Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA.
Clin Infect Dis. 2021 Jul 1;73(1):e1-e8. doi: 10.1093/cid/ciaa438.
Up-to-date estimates of the burden of norovirus, a leading cause of acute gastroenteritis (AGE) in the United States, are needed to assess the potential value of norovirus vaccines in development. We aimed to estimate the rates, annual counts, and healthcare charges of norovirus-associated ambulatory clinic encounters, emergency department (ED) visits, hospitalizations, and deaths in the United States.
We analyzed administrative data on AGE outcomes from 1 July 2001 through 30 June 2015. Data were sourced from IBM MarketScan Commercial and Medicare Supplemental Databases (ambulatory clinic and ED visits), the Healthcare Utilization Project National Inpatient Sample (hospitalizations), and the National Center for Health Statistics multiple-cause-of-mortality data (deaths). Outcome data (ambulatory clinic and ED visits, hospitalizations, or deaths) were summarized by month, age group, and setting. Healthcare charges were estimated based on insurance claims. Monthly counts of cause-unspecified gastroenteritis-associated outcomes were modeled as functions of cause-specified outcomes, and model residuals were analyzed to estimate norovirus-associated outcomes. Healthcare charges were estimated by applying average charges per cause-unspecified gastroenteritis encounter to the estimated number of norovirus encounters.
We estimate 900 deaths (95% confidence interval [CI], 650-1100), 109 000 hospitalizations (95% CI, 80 000-145 000), 465 000 ED visits (95% CI, 348 000-610 000), and 2.3 million ambulatory clinic encounters (95% CI, 1.7-2.9 million) annually due to norovirus, with an associated $430-$740 million in healthcare charges.
Norovirus causes a substantial health burden in the United States each year, and an effective vaccine could have important public health impact.
需要最新估计美国急性胃肠炎(AGE)主要病因诺如病毒的负担,以评估正在开发的诺如病毒疫苗的潜在价值。本研究旨在估计美国诺如病毒相关的门诊诊所就诊、急诊(ED)就诊、住院和死亡的发生率、年计数和医疗费用。
我们分析了 2001 年 7 月 1 日至 2015 年 6 月 30 日期间 AGE 结局的行政数据。数据来源于 IBM MarketScan 商业和医疗保险补充数据库(门诊诊所和 ED 就诊)、医疗保健利用项目全国住院样本(住院)和国家卫生统计中心多病因死亡率数据(死亡)。根据月份、年龄组和就诊场所汇总结局数据(门诊诊所和 ED 就诊、住院或死亡)。根据保险索赔估计医疗费用。将未明确病因的胃肠炎相关结局的每月计数建模为明确病因结局的函数,并对模型残差进行分析以估计诺如病毒相关结局。通过将每例未明确病因胃肠炎就诊的平均费用应用于估计的诺如病毒就诊次数来估计医疗费用。
我们估计每年有 900 例死亡(95%置信区间 [CI],650-1100)、109 000 例住院(95%CI,80 000-145 000)、465 000 例 ED 就诊(95%CI,348 000-610 000)和 230 万例门诊就诊(95%CI,170 万-290 万),由诺如病毒引起,与医疗费用 4.3-7.4 亿美元相关。
诺如病毒每年在美国造成重大的健康负担,如果有一种有效的疫苗,可能会对公共卫生产生重要影响。